FDA Compounding Committee Is a Stacked Deck
Conflicts of interests and rampant biases on the committee advising FDA on the new compounding rules? Yes—in abundance! Related Action Alert! Last week, we wrote about the FDA’s latest efforts to regulate compounding pharmacies in its draft Memorandum of Understanding (MOU). Although these provisions are still in the process of being completed, it’s looking increasingly likely […]